Natera, INC Form 4 insider transactions

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, sold 1,334 shares of common stock to cover tax obligations related to RSU vesting.

Natera's President and Chief Business Officer, John Fesko, acquired 6,135 shares of common stock through immediately vested Restricted Stock Units.

Natera, Inc. director Ruth Brinkley Williams received 73 fully vested Restricted Stock Units as future compensation for her board service, effective January 30, 2026.

Natera, Inc. director Herm Rosenman received 99 fully vested Restricted Stock Units as compensation for board service.

Natera, Inc. Director Gail Boxer Marcus received 91 fully vested Restricted Stock Units in lieu of quarterly retainer fees for board service.

Natera Director Rowan E Chapman acquired 97 shares of common stock through a fully vested RSU issuance as compensation for board service.

Natera, Inc. Director Roelof Botha received 112 fully vested Restricted Stock Units as compensation for board service, valued at $26,875.

Natera Director Monica Bertagnolli acquired 70 shares of common stock through fully vested Restricted Stock Units as part of her quarterly retainer for board service.

Natera, Inc. Director Roy D. Baynes received 70 fully vested Restricted Stock Units as compensation for his board service.

Natera's CEO, Steven Leonard Chapman, sold common stock totaling 5,970 shares to cover tax withholding obligations related to RSU vesting.

Natera's Chief Financial Officer, Michael Burkes Brophy, reported multiple sales of common stock totaling 5,064 shares between January 27-29, 2026, primarily for tax obligations and under a 10b5-1 plan.

Jonathan Sheena, Natera's Co-Founder and Director, sold shares totaling 482 units to cover tax obligations related to RSU vesting under a Rule 10b5-1 plan.

Natera's Chief Legal Officer, Daniel Rabinowitz, sold shares to cover tax obligations related to RSU vesting.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold shares to cover tax obligations related to RSU vesting.

Natera's President and Chief Business Officer, John Fesko, sold shares to cover tax obligations related to RSU vesting under a pre-arranged 10b5-1 plan.

Jonathan Sheena, Natera's Co-Founder and Director, sold 1,500 shares of common stock on January 23, 2026, through a pre-arranged 10b5-1 trading plan.

Natera's CEO and President, Steven Leonard Chapman, reported sales of common stock totaling 73,522 shares to cover tax obligations related to Restricted Stock Unit vesting.

Natera's Chief Financial Officer, Michael Burkes Brophy, reported sales of common stock totaling 61,123 shares, primarily for tax obligations and under a pre-arranged trading plan.

Natera Co-Founder Jonathan Sheena reported sales of common stock, primarily for tax obligations and under a pre-arranged trading plan, alongside the vesting of Restricted Stock Units.

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, reported sales of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Solomon Moshkevich, Natera's President of Clinical Diagnostics, sold common stock totaling 23,498 shares to cover tax withholding obligations from vested Restricted Stock Units.

Natera's President and Chief Business Officer, John Fesko, sold common stock totaling 18,145 shares to cover tax obligations related to RSU vesting.

Natera's Chief Financial Officer, Michael Burkes Brophy, vested 59,596 shares of common stock on January 14, 2026, as part of a pre-planned performance-based Restricted Stock Unit award.

Natera Inc.'s CEO and President, Steven Leonard Chapman, acquired 152,718 shares of common stock through the vesting of performance-based Restricted Stock Units.

Natera's President and Chief Business Officer, John Fesko, vested 44,698 shares of common stock on January 14, 2026, following the certification of a performance milestone.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, vested 44,698 shares of common stock on January 14, 2026, following the certification of a performance milestone.

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, acquired 37,248 shares of common stock through the vesting of a performance-based Restricted Stock Unit award.

Natera Co-Founder and Director Jonathan Sheena acquired 7,450 shares of common stock through the vesting of a performance-based Restricted Stock Unit award.

Natera Co-Founder Jonathan Sheena exercised options to acquire 39,615 shares of common stock at $9.59 per share.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 2,951 shares of common stock for approximately $675,800 under a pre-arranged 10b5-1 trading plan.